- Home
- SBFM vs CANF Comparison
SBFM vs CANF Comparison
Compare SBFM & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBFM
- CANF
- Stock Information
- Founded
- SBFM 2006
- CANF 1994
- Country
- SBFM United States
- CANF Israel
- Employees
- SBFM N/A
- CANF N/A
- Industry
- SBFM Biotechnology: Pharmaceutical Preparations
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- SBFM Health Care
- CANF Health Care
- Exchange
- SBFM Nasdaq
- CANF Nasdaq
- Market Cap
- SBFM 4.9M
- CANF 7.9M
- IPO Year
- SBFM N/A
- CANF N/A
- Fundamental
- Price
- SBFM $1.39
- CANF $1.09
- Analyst Decision
- SBFM Strong Buy
- CANF Strong Buy
- Analyst Count
- SBFM 1
- CANF 2
- Target Price
- SBFM $15.00
- CANF $14.00
- AVG Volume (30 Days)
- SBFM 4.4M
- CANF 422.0K
- Earning Date
- SBFM 05-19-2025
- CANF 05-13-2025
- Dividend Yield
- SBFM N/A
- CANF N/A
- EPS Growth
- SBFM N/A
- CANF N/A
- EPS
- SBFM N/A
- CANF N/A
- Revenue
- SBFM $34,874,283.00
- CANF $674,000.00
- Revenue This Year
- SBFM $192.48
- CANF $461.72
- Revenue Next Year
- SBFM N/A
- CANF N/A
- P/E Ratio
- SBFM N/A
- CANF N/A
- Revenue Growth
- SBFM 44.75
- CANF N/A
- 52 Week Low
- SBFM $1.17
- CANF $1.22
- 52 Week High
- SBFM $33.60
- CANF $4.69
- Technical
- Relative Strength Index (RSI)
- SBFM 38.67
- CANF 34.28
- Support Level
- SBFM $1.17
- CANF $1.13
- Resistance Level
- SBFM $1.59
- CANF $1.19
- Average True Range (ATR)
- SBFM 0.16
- CANF 0.11
- MACD
- SBFM 0.04
- CANF -0.02
- Stochastic Oscillator
- SBFM 51.28
- CANF 1.35
About SBFM Sunshine Biopharma Inc.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).